Cargando…
Modelling metabolic diseases and drug response using stem cells and organoids
Metabolic diseases, including obesity, diabetes mellitus and cardiovascular disease, are a major threat to health in the modern world, but efforts to understand the underlying mechanisms and develop rational treatments are limited by the lack of appropriate human model systems. Notably, advances in...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449917/ https://www.ncbi.nlm.nih.gov/pubmed/36071283 http://dx.doi.org/10.1038/s41574-022-00733-z |
_version_ | 1784784406226927616 |
---|---|
author | Hu, Wenxiang Lazar, Mitchell A. |
author_facet | Hu, Wenxiang Lazar, Mitchell A. |
author_sort | Hu, Wenxiang |
collection | PubMed |
description | Metabolic diseases, including obesity, diabetes mellitus and cardiovascular disease, are a major threat to health in the modern world, but efforts to understand the underlying mechanisms and develop rational treatments are limited by the lack of appropriate human model systems. Notably, advances in stem cell and organoid technology allow the generation of cellular models that replicate the histological, molecular and physiological properties of human organs. Combined with marked improvements in gene editing tools, human stem cells and organoids provide unprecedented systems for studying mechanisms of metabolic diseases. Here, we review progress made over the past decade in the generation and use of stem cell-derived metabolic cell types and organoids in metabolic disease research, especially obesity and liver diseases. In particular, we discuss the limitations of animal models and the advantages of stem cells and organoids, including their application to metabolic diseases. We also discuss mechanisms of drug action, understanding the efficacy and toxicity of existing therapies, screening for new treatments and pursuing personalized therapies. We highlight the potential of combining stem cell-derived organoids with gene editing and functional genomics to revolutionize the approach to finding treatments for metabolic diseases. |
format | Online Article Text |
id | pubmed-9449917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-94499172022-09-07 Modelling metabolic diseases and drug response using stem cells and organoids Hu, Wenxiang Lazar, Mitchell A. Nat Rev Endocrinol Review Article Metabolic diseases, including obesity, diabetes mellitus and cardiovascular disease, are a major threat to health in the modern world, but efforts to understand the underlying mechanisms and develop rational treatments are limited by the lack of appropriate human model systems. Notably, advances in stem cell and organoid technology allow the generation of cellular models that replicate the histological, molecular and physiological properties of human organs. Combined with marked improvements in gene editing tools, human stem cells and organoids provide unprecedented systems for studying mechanisms of metabolic diseases. Here, we review progress made over the past decade in the generation and use of stem cell-derived metabolic cell types and organoids in metabolic disease research, especially obesity and liver diseases. In particular, we discuss the limitations of animal models and the advantages of stem cells and organoids, including their application to metabolic diseases. We also discuss mechanisms of drug action, understanding the efficacy and toxicity of existing therapies, screening for new treatments and pursuing personalized therapies. We highlight the potential of combining stem cell-derived organoids with gene editing and functional genomics to revolutionize the approach to finding treatments for metabolic diseases. Nature Publishing Group UK 2022-09-07 2022 /pmc/articles/PMC9449917/ /pubmed/36071283 http://dx.doi.org/10.1038/s41574-022-00733-z Text en © Springer Nature Limited 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Hu, Wenxiang Lazar, Mitchell A. Modelling metabolic diseases and drug response using stem cells and organoids |
title | Modelling metabolic diseases and drug response using stem cells and organoids |
title_full | Modelling metabolic diseases and drug response using stem cells and organoids |
title_fullStr | Modelling metabolic diseases and drug response using stem cells and organoids |
title_full_unstemmed | Modelling metabolic diseases and drug response using stem cells and organoids |
title_short | Modelling metabolic diseases and drug response using stem cells and organoids |
title_sort | modelling metabolic diseases and drug response using stem cells and organoids |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449917/ https://www.ncbi.nlm.nih.gov/pubmed/36071283 http://dx.doi.org/10.1038/s41574-022-00733-z |
work_keys_str_mv | AT huwenxiang modellingmetabolicdiseasesanddrugresponseusingstemcellsandorganoids AT lazarmitchella modellingmetabolicdiseasesanddrugresponseusingstemcellsandorganoids |